Zydus Cadila receives USFDA nod for anti-viral injection USP

Indian pharmaceutical major Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market its anti-viral injection USP Acyclovir in that country.

The Ahmedabad headquartered company will market Acyclovir for injection USP, which is used to treat infections caused by herpes viruses, such as genital herpes, cold sores, shingles and chicken pox, in strengths of 500 mg/vial and 1000 mg/vial.
It will be produced at Zydus Cadila’s formulations manufacturing plant at Moraiya, Ahmedabad.

Zydus Cadila, which discovers, develops, manufactures and markets a broad range of healthcare products, has now more than 120 approvals to its credit and has so far filed over 300 Abbreviated New Drug Applications (ANDAs) since 2003-04.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top